Paper28906290
Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.
Cross RK. Inflamm Bowel Dis, 2017. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis. Papers, record 28906290. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28906290
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adrenal Cortex Hormones | Major topic |
| Antibodies, Monoclonal | Major topic |
| Beclomethasone | Major topic |
| Budesonide | Major topic |
| Colitis, Ulcerative | Major topic |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Severity of Illness Index |
Source PubMed
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42871137 | Stratified by baseline corticosteroid use: which advanced therapy works best for whom in ulcerative colitis? | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42871137 | PubMed |
| 42682644 | Salmonella Typhimurium infection complicating very early-onset inflammatory bowel disease presenting with Pseudo-intussusception: a case report. | Front Pediatr | 2026 | https://conductscience.org/library/papers/42682644 | PubMed |
| 42473331 | Engineered probiotics platform for resolvin E1 biosynthesis confers protection against inflammatory disease. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42473331 | PubMed |
| 42272621 | Progress in the Treatment of Ulcerative Colitis by Targeting NLRP3 Inflammasome. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42272621 | PubMed |
| 40433382 | "Remodeling the intestinal immune microenvironment": immune regulation and tissue regeneration by mesenchymal stem/stromal cells in the repair microenvironment of inflammatory bowel disease. | Front Immunol | 2025 | https://conductscience.org/library/papers/40433382 | PubMed |
| 40222016 | Safety Outcomes in Patients With Ulcerative Colitis Using a Healthcare Administrative Database in the United States. | Inflamm Bowel Dis | 2025 | https://conductscience.org/library/papers/40222016 | PubMed |
| 40168091 | Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. | J Crohns Colitis | 2025 | https://conductscience.org/library/papers/40168091 | PubMed |
| 39671695 | Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program. | Inflamm Bowel Dis | 2025 | https://conductscience.org/library/papers/39671695 | PubMed |
| 39306680 | Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program. | J Crohns Colitis | 2025 | https://conductscience.org/library/papers/39306680 | PubMed |
| 39086989 | Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis. | Ther Adv Gastroenterol | 2024 | https://conductscience.org/library/papers/39086989 | PubMed |
| 38308626 | Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United States. | J Manag Care Spec Pharm | 2024 | https://conductscience.org/library/papers/38308626 | PubMed |
| 37533463 | Thiol-Disulfide Exchange Coordinates the Release of Nitric Oxide and Dexamethasone for Synergistic Regulation of Intestinal Microenvironment in Colitis. | Research (Wash D C) | 2023 | https://conductscience.org/library/papers/37533463 | PubMed |
| 36225410 | Glucocorticoids-Induced Neuropsychiatric Disorders in Patients With Inflammatory Bowel Disease: A Systematic Review. | Cureus | 2022 | https://conductscience.org/library/papers/36225410 | PubMed |
| 34386591 | Clinical characteristics of ulcerative colitis in elderly patients. | JGH Open | 2021 | https://conductscience.org/library/papers/34386591 | PubMed |
| 34165201 | The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. | Aliment Pharmacol Ther | 2021 | https://conductscience.org/library/papers/34165201 | PubMed |
| 33324993 | Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. | Inflamm Bowel Dis | 2021 | https://conductscience.org/library/papers/33324993 | PubMed |
| 32606883 | Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. | Clin Exp Gastroenterol | 2020 | https://conductscience.org/library/papers/32606883 | PubMed |
| 32370215 | Walnut Oil Alleviates Intestinal Inflammation and Restores Intestinal Barrier Function in Mice. | Nutrients | 2020 | https://conductscience.org/library/papers/32370215 | PubMed |
| 30686824 | Intestinal glucocorticoid synthesis enzymes in pediatric inflammatory bowel disease patients. | Genes Immun | 2019 | https://conductscience.org/library/papers/30686824 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28906290
GET https://conductscience.org/api/papers/v1/28906290/authors